company background image
1099 logo

Sinopharm Group SEHK:1099 Voorraadrapport

Laatste prijs

HK$20.55

Marktkapitalisatie

HK$64.1b

7D

1.5%

1Y

3.1%

Bijgewerkt

21 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Sinopharm Group Co. Ltd.

SEHK:1099 Voorraadrapport

Marktkapitalisatie: HK$64.1b

1099 Overzicht aandelen

Sinopharm Group Co. Ltd. houdt zich samen met haar dochterondernemingen bezig met de groot- en detailhandel in farmaceutische producten, medische apparatuur en gezondheidsproducten in de Volksrepubliek China. Meer informatie

Beloningen

Verhandeld tegen 63.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 4.54% per jaar groeien

Betaalt een betrouwbaar dividend van 4.51%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft een hoog schuldenniveau


Sinopharm Group Co. Ltd. Concurrenten

Guangzhou Baiyunshan Pharmaceutical Holdings

SEHK:874

HK$47.7b

Tycoon Group Holdings

SEHK:3390

HK$2.9b

IVD Medical Holding

SEHK:1931

HK$2.9b

Shanghai Pioneer Holding

SEHK:1345

HK$2.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sinopharm Group
Historische aandelenkoersen
Huidige aandelenkoersHK$20.55
52 Week HoogtepuntHK$23.65
52 Week LaagHK$16.02
Bèta0.86
11 maand verandering1.48%
3 maanden verandering10.72%
1 Jaar Verandering3.06%
33 jaar verandering11.08%
5 jaar verandering-21.41%
Verandering sinds IPO10.96%

Recent nieuws en updates

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Nov 06
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Oct 04
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Recent updates

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Nov 06
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Oct 04
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Aug 23
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Jul 27
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Jun 16
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

May 13
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Mar 06
Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Jan 31
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Dec 31
There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

Nov 29
Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Nov 14
If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Nov 01
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sep 20
Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sep 05
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Aug 18
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Aug 02
Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Jun 01
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Apr 26
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Feb 27
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Jan 19
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Is Sinopharm Group (HKG:1099) A Risky Investment?

Nov 18
Is Sinopharm Group (HKG:1099) A Risky Investment?

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Oct 03
Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jul 31
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Jul 10
Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Jun 05
Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Apr 11
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Mar 21
A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Mar 03
Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jan 09
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Dec 19
Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Dec 01
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Sep 10
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Aug 28
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Jun 13
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Jun 06
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

May 24
Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

May 11
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

Mar 20
Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Mar 05
We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Rendement voor aandeelhouders

1099HK HealthcareHK Markt
7D1.5%-0.6%0.4%
1Y3.1%-23.3%12.0%

Rendement versus industrie: 1099 overtrof de Hong Kong Healthcare industrie, die het afgelopen jaar een rendement -23.3 % opleverde.

Rendement versus markt: 1099 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 12 % opleverde.

Prijsvolatiliteit

Is 1099's price volatile compared to industry and market?
1099 volatility
1099 Average Weekly Movement6.1%
Healthcare Industry Average Movement8.2%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.3%

Stabiele aandelenkoers: 1099 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van 1099 is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2003113,635Wanyong Lianwww.sinopharmgroup.com.cn

Sinopharm Group Co. Ltd. houdt zich samen met haar dochterondernemingen bezig met de groot- en detailhandel in farmaceutische producten, medische hulpmiddelen en gezondheidsproducten in de Volksrepubliek China. Het bedrijf is actief in vier segmenten: Farmaceutische Distributie, Medische Hulpmiddelen, Apotheek voor de Kleinhandel en Overige Activiteiten. Het segment Farmaceutische Distributie distribueert farmaceutische producten naar ziekenhuizen, andere distributeurs, apotheken en klinieken.

Sinopharm Group Co. Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Sinopharm Group zich tot de beurswaarde?
1099 fundamentele statistieken
MarktkapitalisatieHK$64.13b
Inkomsten(TTM)HK$9.30b
Inkomsten(TTM)HK$634.51b

6.9x

Koers/Winstverhouding

0.1x

P/S-verhouding

Is 1099 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1099 resultatenrekening (TTM)
InkomstenCN¥590.35b
Kosten van inkomstenCN¥543.16b
BrutowinstCN¥47.18b
Overige uitgavenCN¥38.53b
InkomstenCN¥8.65b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)2.77
Brutomarge7.99%
Nettowinstmarge1.47%
Schuld/Eigen Vermogen Verhouding78.1%

Hoe presteerde 1099 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.5%

Huidig dividendrendement

31%

Uitbetalingsratio